Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

170.69
+2.531.50%
Volume:2.63M
Turnover:447.06M
Market Cap:44.04B
PE:-12.01
High:170.69
Open:167.66
Low:167.52
Close:168.16
52wk High:176.60
52wk Low:141.05
Shares:258.02M
Float Shares:258.02M
Volume Ratio:0.68
T/O Rate:1.02%
Dividend:2.45
Dividend Rate:1.43%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.28
PE(LYR):-12.01

Loading ...

Health Care Roundup: Market Talk

Dow Jones
·
Oct 01

Autagco Signs Non-Binding MOU to Drive Healthcare and Wellness Expansion

TIPRANKS
·
Sep 30

Jefferies Remains a Buy on Humana (HUM)

TIPRANKS
·
Sep 30

Trump Pledges $500 Rebates to 1 Million Medicare Beneficiaries Each, to Be Mailed Starting Oct. 1

TradingKey
·
Sep 30

Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)

TIPRANKS
·
Sep 30

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Sep 30

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Is Ping An Healthcare And Technology (SEHK:1833) Undervalued After Its GlobalCare Launch?

Simply Wall St.
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Inflation Data Release

MT Newswires Live
·
Sep 30

LIVE Markets-TD Cowen Says AI Promises Hospitals a Margin Cure

Reuters
·
Sep 30

Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38

TIPRANKS
·
Sep 30